The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS)

BJU International

Volumn 110, Issue , 2012, Pages

  Gudjónsson, Sigurdur ^a   Bläckberg, Mats ^b   Chebil, Gunilla ^b   Jahnson, Staffan ^c   Olsson, Hans ^d   Bendahl, Pär Ola ^c   Månsson, Wiking ^a   Liedberg, Fredrik ^a,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e Vaxjo County Hospital   (Sweden)

Author keywords

biopsies; bladder cancer; bladder mapping; carcinoma in situ (CIS); prostatic urethra

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER MAPPING; BLADDER MUCOSA; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; QUALITY CONTROL; RELIABILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA IN SITU; CYSTECTOMY; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; PROSTATE; SENSITIVITY AND SPECIFICITY; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84863553119     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10654.x     Document Type: Article

References (27)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al,. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-7
2. de Vries RR, Nieuwenhuijzen JA, Vincent A, van Tinteren H, Horenblas S,. Survival after cystectomy for invasive bladder cancer. Eur J Surg Oncol 2010; 36: 292-7
3. Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA,. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004; 45: 292-6
4. Zaak D, Hungerhuber E, Schneede P, et al,. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002; 95: 1234-8
5. Sakamoto N, Tsuneyoshi M, Naito S, Kumazawa J,. An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients. J Urol 1993; 149: 318-21
6. Epstein JI, Amin MB, Reuter VR, Mostofi FK,. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-48
7. Lamm DL,. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573-80
8. De Jager R, Guinan P, Lamm D, et al,. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology. 1991; 38: 507-13
9. Losa A, Hurle R, Lembo A,. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000; 163: 68-72
10. Jakse G, Hall R, Bono A, et al,. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 2001; 40: 144-50
11. Sylvester R, Meijden AVD, Witjes JA, et al,. High grade Ta urothelial carcinoma and carcinoma in Situ of the bladder. In, Soloway M, Carmack A, Khoury S, eds, Bladder Tumors, 2006 edn. Paris: Health Publication Ltd, 2006: 165-88
12. Herr HW, Al-Ahmadie H, Dalbagni G, Reuter VE,. Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity? BJU Int 2010; 106: 1499-501
13. Fujimoto N, Harada S, Terado M, Sato H, Matsumoto T,. Multiple biopsies of normal-looking urothelium in patients with superficial bladder cancer: are they necessary? Int J Urol 2003; 10: 631-5
14. van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C,. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999; 35: 267-71
15. Hara T, Takahashi M, Gondo T, et al,. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases. Int J Urol 2009; 16: 293-8
16. Thorstenson A, Schumacher MS, Wiklund NP,. Diagnostic random bladder biopsies: reflections from a population-based cohort of 538 patients. Scand J Urol Nephrol 2010; 44: 11-20
17. Kulkarni GS, Hakenberg OW, Gschwend JE, et al,. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010; 57: 60-70
18. Denzinger S, Otto W, Fritsche HM, et al,. Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol 2007; 14: 995-9
19. Varol C, Thalmann GN, Burkhard FC, Studer UE,. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol 2004; 172: 937-42
20. Mak RH, Zietman AL, Heney NM, Kaufman DS, Shipley WU,. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008; 102: 1345-53
21. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2011; 59: 997-1008
22. Hind A, Ventura L, Leocata P, et al,. Histopathological study of 110 cystectomy specimens for bladder cancer by an original mapping method. J Exp Clin Cancer Res 1998; 17: 59-64
23. Vicente-Rodriguez J, Chechile G, Algaba F, Amaral J Jr,. Value of random endoscopic biopsy in the diagnosis of bladder carcinoma in situ. Eur Urol 1987; 13: 150-2
24. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M,. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171: 135-8
25. Jocham D, Witjes F, Wagner S, et al,. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 862-6
26. Fradet Y, Grossman HB, Gomella L, et al,. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178: 68-73
27. Stenzl A, Burger M, Fradet Y, et al,. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010; 184: 1907-13